★ WIDE MOAT STOCKS COMPARISON ★

Checking

Stock Comparison

Abbott Laboratories vs Johnson & Johnson

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$186.5B
Gross margin (TTM)56.8%
Operating margin (TTM)17%
Net margin (TTM)11.7%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-08-09
Moat score
22/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Johnson & Johnson

JNJ · New York Stock Exchange

Market cap (USD)$536.5B
Gross margin (TTM)70.5%
Operating margin (TTM)26.8%
Net margin (TTM)21.5%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-08-10
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Johnson & Johnson's moat claims, evidence, and risks.

View JNJ analysis

Comparison highlights

  • Moat score gap: Johnson & Johnson leads (73 / 100 vs 22 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 9 segments (27% in Cardiovascular and Electrophysiology Devices); Johnson & Johnson has 2 segments (64.7% in Innovative Medicine).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
  • Moat breadth: Abbott Laboratories has 1 moat types across 1 domains; Johnson & Johnson has 3 across 2.

Primary market context

Abbott Laboratories

Cardiovascular and Electrophysiology Devices

Market

Rhythm management, electrophysiology, heart failure, vascular and structural-heart devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers and cardiovascular clinicians

Role

Implantable and procedure-based device manufacturer

Revenue share

27%

Johnson & Johnson

Innovative Medicine

Market

Branded prescription pharmaceuticals (biopharma)

Geography

Global

Customer

Wholesalers, hospitals, retailers, healthcare professionals, payers

Role

Drug discovery, development, manufacturing, commercialization

Revenue share

64.7%

Side-by-side metrics

Abbott Laboratories
Johnson & Johnson
Ticker / Exchange
ABT - New York Stock Exchange
JNJ - New York Stock Exchange
Market cap (USD)
$186.5B
$536.5B
Gross margin (TTM)
56.8%
70.5%
Operating margin (TTM)
17%
26.8%
Net margin (TTM)
11.7%
21.5%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Drug Manufacturers - General
HQ country
US
US
Primary segment
Cardiovascular and Electrophysiology Devices
Innovative Medicine
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
22 / 100
73 / 100
Moat domains
Demand
Legal, Demand
Last update
2026-08-09
2026-08-10

Moat coverage

Shared moat types

No overlap yet.

Abbott Laboratories strengths

Installed Base Consumables

Johnson & Johnson strengths

IP Choke PointTraining Org Change CostsBrand Trust

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

11.9%

Pediatric Nutrition

Oligopoly

8.1%

Adult Nutrition

Oligopoly

8.9%

Core Laboratory Diagnostics

Oligopoly

11.3%

Rapid and Molecular Diagnostics

Competitive

6%

Cancer Diagnostics

Competitive

7.3%

Diabetes Care (CGM and glucose monitoring)

Oligopoly

17.4%

Cardiovascular and Electrophysiology Devices

Oligopoly

27%

Neuromodulation Devices

Oligopoly

2.1%

Johnson & Johnson segments

Full profile >

Innovative Medicine

Competitive

64.7%

MedTech

Oligopoly

35.3%

Act on this comparison

Turn a two-stock debate into a systemSee the systematic rankings that surface stocks like ABT and JNJ, with backtests and current holdings.

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.